Tumor-associated macrophages (TAMs) are attractive targets for immunotherapy. Recently, studies in animal models showed that treatment with an anti-TAM antibody directed against the scavenger receptor MARCO resulted in suppression of tumor growth and metastatic dissemination. Here we investigated the expression of MARCO in relation to other macrophage markers and immune pathways in a non-small cell lung cancer (NSCLC) cohort (n 5 352). MARCO, CD68, CD163, MSR1 and programmed death ligand-1 (PD-L1) were analyzed by immunohistochemistry and immunofluorescence, and associations to other immune cells and regulatory pathways were studied in a subset of cases (n 5 199) with available RNA-seq data. We observed a large variation in macrophage density between cases and a strong correlation between CD68 and CD163, suggesting that the majority of TAMs present in NSCLC exhibit a protumor phenotype. Correlation to clinical data only showed a weak trend toward worse survival for patients with high macrophage infiltration. Interestingly, MARCO was expressed on a distinct subpopulation of TAMs, which tended to aggregate in close proximity to tumor cell nests. On the transcriptomic level, we found a positive association between MARCO gene expression and general immune response pathways including strong links to immunosuppressive TAMs, T-cell infiltration and immune checkpoint molecules. Indeed, a higher macrophage infiltration was seen in tumors expressing PD-L1, and macrophages residing within tumor cell nests co-expressed MARCO and PD-L1. Thus, MARCO is a potential new immune target for anti-TAM treatment in a subset of NSCLC patients, possibly in combination with available immune checkpoint inhibitors.
tissue. Another approach is to hit targets that reprogram TAMs of a protumor phenotype to adopt a proinflammatory tumor suppressive phenotype. 5 The scavenger receptor MARCO is normally expressed on restricted subpopulations of macrophages in secondary lymphoid organs. 6 Here it binds modified self-antigens such as apoptotic cells but also foreign antigens and acts in this respect as a pattern recognition receptor. The receptor is relatively conserved and exhibits similar expression patterns in mouse and human. In mouse melanoma and breast cancer models, treatment with antibodies targeting MARCO resulted in reduced tumor growth and inhibition of metastasis and a switch into a more proinflammatory macrophage phenotype. 7 This previous study, by members of our group, was the first to explore repolarization of MARCO-positive TAMs and to show MARCO-expressing TAMs to be present in human breast cancer and melanoma tissue. As MARCO supports proinflammatory signals, it has the potential to work well in combination with other immunotherapy modalities such as T-cell-directed antibodies. Lung cancer is the most common cancer type and the leading cause of cancer-related deaths worldwide. 8 Although treatment advancements have occurred, such as introduction of targeted therapies, only small improvements have been observed in the overall survival. 9 Immune-modulating agents inhibiting negative T-cell checkpoints like cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) have shown to lead to tumor regression in several tumor types. In lung cancer, antibodies targeting PD-1 have been approved for treatment of advanced non small cell lung cancer (NSCLC) and this type of treatment is now partially replacing traditional systemic treatments regimes. [10] [11] [12] [13] However, it has been estimated that only 20% of NSCLC patients demonstrate long term benefit from PD-1 inhibition and additional immune regulatory pathways, therefore, need to be explored. 14 Studies evaluating the role of macrophages in NSCLC have shown conflicting results. [15] [16] [17] [18] [19] [20] One reason for these discrepancies may be the heterogeneity and plasticity of TAMs related to host factors, smoking and co-occurring inflammatory and infectious lung disease in different study populations. Thus, more studies are needed to understand the clinical value of TAM characterization. To our knowledge, no data have been published on MARCO expression in lung cancer related macrophages. Here we aim to characterize TAMs in a consecutive NSCLC cohort and associations to clinicopathological parameters. A specific goal was to investigate TAMs expressing the scavenger receptor MARCO in relation to other macrophage markers, inflammatory pathways, immunotherapy targets and immune cells.
Material and Methods

Patients and tumor tissues
This study is based on 352 NSCLC patients surgically treated at Uppsala University Hospital between 2006 and 2010. 21 Clinical parameters were obtained from the records of the populationbased Uppsala-€ Orebro Regional Lung Cancer Registry-age at diagnosis, sex, smoking history, tumor histology, tumor stage, performance status (according to WHO) and overall survival (Table 1) . Representative formalin-fixed paraffin-embedded tumor tissue blocks were used to construct tissue microarrays (TMAs). Using a manual tissue arrayer (MTA-1, Beecher Instruments, Sun Prairie, CA), the TMAs were constructed with duplicate 1 mm cores as described earlier in a previous study. 22 The study was conducted in accordance with the Declaration of Helsinki and the Swedish Ethical Review Act (approved by the Ethical Review Board in Uppsala, reference 2012/532).
Immunohistochemistry
Sections (4 lm) from the TMAs were mounted on adhesive slides (SuperFrost Plus, Thermo Scientific) and used for immunohistochemistry (IHC) analysis. The slides were incubated for 45 min at 608C, followed by deparaffinization and hydration using xylene and graded alcohols to distilled water. Using 0.3% hydrogen peroxide in 95% ethanol for 5 min endogenous peroxidase was blocked and for antigen retrieval the slides were pressure-boiled for 4 min at 1258C in citrate buffer pH 6 (Lab Vision). Automated IHC was performed on an Autostainer 480 instrument (Thermo Fisher Scientific) as previously described, 23 were scanned at 203 magnification to generate high-resolution digital images. At the start of the project, the antibody dilutions for the macrophage markers (CD68, CD163, MSR1 and MARCO) were titrated on normal lung tissue to obtain a clear and specific staining on alveolar macrophages.
Annotation of immunohistochemistry
The scanned images were viewed in ImageScope (Aperio Technologies) and the expression of CD68, CD163, MSR1 and MARCO was evaluated based on the density of positive cells with a macrophage morphology using a four-graded scale: (0) no macrophages, (1) few macrophages, (2) moderate amount of macrophages and (3) large amount of macrophages. The macrophage density was determined separately for the tumor, stroma and lumen compartments. The scores for each compartment were then multiplied with the relative size of the compartment (in percentage, 0-100) to generate a tumor, stroma and lumen score, respectively. These scores were then summarized for each case to produce a total score, ranging between 0 and 300. The duplicate cores were treated as one "unit." The fractions of tumor-, stroma-and luminal areas and the scores for each compartment were based on the two cores combined.
The evaluation was performed independently by two investigators (LLF and JB), and cases with a discordant scoring were discussed to reach a joint consensus. The membranous staining of PD-L1 was evaluated based on the fraction of stained tumor cells. The cases were then annotated as either negative (<1%) or positive (>1%).
Immunofluorescence
As previously described in Georgoudaki et al., 7 4-lm-thick sections were fixed in cold acetone for 3 min and rinsed in phosphate-buffered saline (PBS). Before staining, tissue sections were blocked for 30 min with 5% goat serum (DakoCytomation) in PBS. Primary antibodies were incubated overnight at 48C, followed by washing with PBS and staining of the secondary antibodies for 1 hr at room temperature. The following antibodies were used: rabbit-anti-human MARCO (ab103311, Abcam) and mouse-anti-human CD163 (MCA1853, BioRad), secondary goat-anti-rabbit IgG(H 1 L) AF555 and goat-antimouse IgG(H 1 L) AF647 (A21429 and A21236, Life Technologies). The tissue sections were further stained with directly conjugated antibodies, anti-human CD68 AF488 (sc-20060, Santa Cruz Biotechnology) and anti-human PD-L1 AF647 (ab209960, Abcam), for 1 hr. After all incubations, the tissue sections were washed with PBS. The samples were mounted with Prolong Diamond mounting medium (Invitrogen). Images were collected using a confocal microscope (Zeiss LSM880) and analyzed using ImageJ software.
RNA sequencing
Fresh frozen tumor tissue was available for 199 of the 352 patients included in this study. RNA was extracted from tissue sections using the RNeasy Mini Kit (Qiagen) in accordance with the manufacturer's protocol. RNA quality was analyzed with Agilent 2100 Bioanalyzer system (Agilent Biotechnologies) using the RNA 6000 Nano Labchip Kit. Utilizing polyAselection mRNA was captured prior to library preparation using the Illumina TruSeq RNA Sample Prep Kit v2, which was followed by sequencing on an Illumina HiSeq2500 instrument. The analysis of the RNA-seq data is thoroughly described in Djureinovic et al.
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Gene expression and network enrichment analysis Association of MARCO gene expression to other genes was evaluated by Spearman rank correlation in the RNAseq data set. The significance of the Spearman rank correlation coefficients was estimated via p values adjusted for multiple testing (FDR), 25 199 cases 20,440 genes. To investigate the relationships between MARCO and potentially relevant gene sets such as KEGG pathways 26 and Gene Ontology 27, 28 (GO) terms, we used a method of network enrichment analysis (NEA) 29, 30 with features similar to the commonly used gene 
Tumor Immunology and Microenvironment
La Fleur et al.
set overrepresentation analysis (ORA). 31 While ORA estimates significance via gene set overlap, NEA considers connectivity between a pair of gene sets in a global gene interaction network. The networks are derived from comprehensive data integration and are sufficiently dense to be able to detect multiple enrichment cases for a moderate size experimental gene set. Therefore, the sensitivity of NEA strongly exceeds that of ORA, given the same specificity level. 30 In this analysis, we used a union of two global networks PathwayComnmons 32 and FunCoup 33, 34 with in total 2 million edges (i.e., links) between 19,000 gene nodes. Another special feature of NEA, used in this study, is the ability to evaluate enrichment of a single gene against a gene set. The network enrichment analysis was conducted against GO terms (with minimum of 10 and maximum of 300 member genes) and KEGG pathways, so that in total of 4,154 functional gene sets (FGS) were used. NEA was executed with R package NEArender 35 and visualized at the website https://www.evinet.org/.
Statistics
Correlations between macrophage markers were calculated using the Spearman's rank correlation. The macrophage density in PD-L1-positive and negative cases was compared using the two-sample Student's t test. The macrophage tumor scores for the markers (CD163, CD68, MSR1, and MARCO) were divided into quantiles (Q1-Q4). Standard descriptive statistics were used to analyze differences in frequencies between the macrophage markers and the demographical and clinical characteristics. To evaluate the macrophage markers in relation to overall survival Kaplan-Meier curves were generated. Survival time was defined as the interval between the date for surgery and the date of death, follow-up at 60 months or end of follow-up. The relative risk of death of all causes was expressed as hazard ratios (HR) with 95% confidence intervals (CI) using univariate and multivariate Cox regression models. The multivariate models were adjusted for gender, age at surgery, pathological stage, smoking status and performance status. All tests were two-sided and statistical significance was considered at a 5% level. The analyses were performed using R 3.1.1.
Results
Tumor-associated macrophages in NSCLC are predominantly of a protumor phenotype
To evaluate the presence of TAMs in NSCLC patients, a TMA consisting of a total of 352 patients were stained for CD68, CD163, MSR1 and MARCO. The pan-macrophage marker CD68 is widely used for detection of macrophages and CD163 and MSR1 are both markers associated with macrophages of a protumor phenotype. 17, 18 MARCO is a recently characterized scavenger receptor with unknown function on TAMs. The infiltration of macrophages positive for each marker by IHC was evaluated in the tumor, stroma and lumen (for adenocarcinomas with glandular differentiation) compartments, respectively, and scored as described above. There was a large variation in the density of macrophages between individual patients and between the different compartments (Fig. 1a) . Some cases had few macrophages in the tumor cell compartment whereas other cases were seen with a rich infiltration. A similar pattern was seen in the stromal compartment. The total score ranged from 0 to 300 in adenocarcinomas and 100 to 300 in squamous cell carcinomas when looking at CD68-positive macrophages (Fig. 1b) . The mean and distribution of the CD163 scores were similar to the CD68 scores. The scores for MSR1 and MARCO were lower, especially for MARCO suggesting expression on a subpopulation of TAMs. This was observed in the tumor cell and stromal compartments (Fig. 1cd) . Most differentiated adenocarcinomas with gland formation had more or less macrophages within the glandular lumen compartments with uniform scores for all four markers (Fig. 1e) . When comparing the scores of the different markers a strong correlation was seen between CD68 and CD163, whereas the correlation of MARCO to the other markers was weaker (Fig. 1f) .
TAMs in the tumor compartment and clinical and demographical characteristics
The macrophage density score from the tumor compartment had the strongest associations to the clinical data and was consequentially selected for univariate and multivariate analysis. A total of 210 (59.7%) out of 352 NSCLC patients were classified as adenocarcinomas. There were no statistically significant associations between the scores of macrophage markers and clinical and the demographical characteristics except for MSR1 and gender, and MARCO and performance status (Supporting Information, Table S1 ). However, a higher proportion of females had a low (Q1) density of infiltrating macrophages, whereas current smokers were somewhat more common among patients with high (Q4) marker expression. For patients identified with a squamous cell carcinoma the division into quantiles resulted in small groups, making it difficult to draw any reliable conclusions (Supporting Information, Table S2 ).
In patients with adenocarcinoma, cases with high (Q4) versus low (Q1) number of positive macrophages for all macrophage markers exhibited a trend toward worse overall survival (Fig. 2) . For example, the three-year survival for low (Q1) and high (Q4) CD163-positive macrophages was 62.3% (95% CI 51.0-76.1%) and 49.1% (95% CI 37.3-64.5%), respectively. Following adjustment for gender, age at surgery, pathological stage, smoking history and performance status, there was no evidence of differences in all-cause mortality between densities of positive macrophages for any of the four markers (Supporting Information, Table S3 ). As expected, pathological stage, smoking status and performance status were all independent predictors of all-cause mortality. 36 For patients with squamous cell carcinoma, a tendency for worse overall survival was observed for patients with high infiltration of MARCO-positive TAMs only (Supporting Information, Fig. S1 ).
MARCO expression defines a specific subset of TAMs
The subgroup of MARCO positive macrophages was investigated in more detail. A variable fraction of MARCO-positive macrophages in relation to CD68-positive macrophages could be seen in the tumor and stroma compartment, respectively. In some cases containing many CD68-positive macrophages, no MARCO-positive macrophages could be observed. Conversely, there were cases with a high density of both CD68 macrophages and MARCO macrophages (Fig. 3a) . Multiplex immunofluorescence staining of fresh frozen sections from samples with high density of CD68, CD163-and MARCOpositive cells confirmed a co-expression of these markers in 
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PD-L1-positive tumors have a higher infiltration of TAMs
To further study and investigate the relevance for immunotherapy, we evaluated the membranous positivity of PD-L1 in the tumor cells of TMA cases. When comparing PD-L1-negative (n 5 205) tumors to positive (n 5 147), the infiltration of macrophages into the tumor compartment was generally higher in the PD-L1-positive tumors, and this applied for both adenocarcinoma (Fig. 4a) and squamous cell carcinoma (Fig. 4b) . Co-stainings of PD-L1, MARCO and CD68 revealed MARCO-positive macrophages in direct contact with PD-L1-positive tumor cells (Fig. 4c) . In addition, co-localization of MARCO and PD-L1 was detected in the cytoplasm and membrane of macrophages. These data indicate that MARCO-positive TAMs could be targeted with anti-MARCO and PD-L1 antibodies in combination. This could be important especially in light of the positioning of this TAM population within the tumor cell nests and surrounding stroma.
MARCO gene expression is linked to immune biology
Gene expression was studied in a subset of 199 cases from the TMA cohort with available RNA-seq data. Genes characteristic for macrophages, different subsets of T-cells and checkpoint molecules were identified based on published literature (Fig.   5a ) and the similarity of their expression profiles to that of MARCO expression was estimated with Spearman rank correlation (Fig. 5b) . The gene expression of MARCO correlated positively (FDR < 0.01 and R > 0.2126212) to several genes linked to immunosuppressive TAMs (CD68, CD163, MSR1, IL4R, CHIA, TGFB1 and IL10), whereas no correlation could be observed to inducible nitric oxide synthase (NOS2), typically expressed by macrophages with antitumor phenotype. MARCO expression was also positively correlated with genes linked to regulatory T-cells (FOXP3, TGFB1, IL10, EBI3, PDCD1 and 
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, TIGIT, BTLA, HAVCR2 and LAG3), cytotoxic T-cells (CD8A, PRF1, GZMA and GZMB) and to immune checkpoint molecules PD-L1 (CD274), VISTA (VSIR), PD-1 (PDCD1) and CTLA4. In Figure 5c , expression of the selected genes and MARCO is presented as a two-way hierarchical clustering across the RNAsequenced cohort of patient samples. We observed four distinct gene clusters that represented regulatory T-cells (green), immunosuppressive macrophages (purple), cytotoxic T-cells (orange) and exhausted T-cells (blue). Interestingly, the patient samples were distributed in three broader patterns. One group (right side of panel 5c) were seen with an overall high expression of the genes in the four immune gene clusters. Another group generally displayed overall low expression of the different immune-regulatory genes (middle part of panel 5c). In some patients (left side of panel 5c) more specific patterns emerged. High expression of immunosuppressive macrophage genes, including MARCO, was seen in combination with expression preferentially in the T-regulatory cluster, and to some extent also in association with the T-exhausted gene cluster. Clinical parameters such as histological subtype of NSCLC, smoking history or gender were not associated with the gene expression patterns in the clustering analysis.
A network enrichment analysis (NEA) was conducted against Gene Ontology (GO) terms and KEGG pathways and six of the gene sets analyzed above (Fig. 5a) . However, first we analyzed enrichment of MARCO itself, taken as a gene node. As there is limited published data on MARCO in relation to its regulation and physical interactions, MARCO was poorly covered with known or predicted links (n 5 8) in the global network dataset. The analysis yielded as few as 12 enriched functional gene sets (FGS) (NEA FDR < 0.01) out of the total of 4154. A more detailed investigation revealed that these patterns were mostly determined by a single link between MARCO and TGFB1. To amplify the power of the NEA strategy, genes with the strongest correlation to MARCO were analyzed. We reasoned that at least a fraction of such genes should be linked to MARCO functionality in lung cancer and could therefore point to relevant FGS, thereby increasing the sensitivity of the network analysis. We compiled six separate lists of the top 100 genes most correlated to MARCO, either positively or negatively, in all available lung cancer samples ('All'), adenocarcinoma (AC) and squamous cell carcinoma (SCC), respectively (Supporting Information, Table S4 ). Although the number of links connecting gene to gene varied (n 5 5-41), the three lists ("All," AC and SCC) with positively correlated genes were all significantly enriched (NEA FDR < 10
224
) in connection to the six immune gene sets defined by us (Fig. 5d) , with exception of one link to the set "checkpoint molecules" versus the adenocarcinoma list. Remarkably, none of the negatively correlated gene lists manifested such enrichment. This indicates that the composition of the gene sets is highly relevant and emphasizes robustness of the MARCO-associated expression pattern across the lung cancer subtypes. More broadly, across all included samples the list of the top 100 positively correlated genes was enriched against 1,166 out of the 4154 FGS (Supporting Information, Table S5 ). This seemingly high fraction of significant findings is typical for NEA, both due to its high sensitivity and because many of the FGSs reflected various vital general cellular processes. Focusing on the immune landscape, 148 of the enriched FGS could be linked to immune biology: general immune response, n 5 29; macrophages, n 5 19; T cells, n 5 23, B cells/plasma cells, n 5 17; natural killer cells, n 5 6; neurophils, n 5 2; cytokines/chemokines, n 5 52 (NEA FDR < 0.01; Supporting Information, Table S6 ). For the respective top 100 gene list of negative correlation with MARCO, 436 FGS were enriched, and again none of these FGSs could be linked to immune biology (Supporting Information, Table S7 ). Thus, in addition to distinct T-cell and macrophage gene sets, MARCO-related genes were significantly involved into a broad range of general immune responses.
Discussion
Here we have evaluated macrophage infiltration in an established NSCLC cohort. Large variations in the density of macrophages could be seen between patients. A strong correlation between the general macrophage marker CD68 and CD163, a marker linked to TAMs with a protumor phenotype, and almost uniform co-expression by immunofluorescence, indicated that the majority of the TAMs were of a protumor phenotype. When comparing the major histologic NSCLC subtypes, the squamous cell carcinomas tended to have a higher TAM density within the tumor islets compared to the adenocarcinomas. Still, tumor macrophage density scores and clinicopathological parameters did not reveal any strong statistical significant associations. But interestingly, a trend for worse overall survival was observed for all tested macrophage markers in adenocarcinoma patients with high macrophage infiltration.
Immunotherapy strategies counteracting negative regulation of T-cells through checkpoint molecules such as CTLA-4 and PD-1 have shown great promise in clinical studies. 14, 37 However, many patients fail to respond despite having favorable predictive tumor characteristics such as high tumor PD-L1 expression, high mutational load and significant T-cell infiltration. 38 This is believed to result from additional independent immunosuppressive regulatory systems in the tumor microenvironment. One suggested mechanism relates to antiinflammatory TAMs and attempts to target these are presently explored. 39, 40 Inhibition of macrophage recruitment has been achieved through CCL2 inhibition, and through targeting the colony stimulating factor-1 receptor (CSF-1R). Both approaches result in decreased macrophage infiltration and reduced tumor growth. [41] [42] [43] Reprogramming of tumor promoting macrophages has been achieved by activation of the toll-like receptor-3, resulting in a transition into antitumor macrophages and tumor regression. 44 Here we have followed up on a study showing that a monoclonal antibody targeting the scavenger receptor MARCO on TAMs resulted in a shift to antitumor functions in mouse tumor models of melanoma, breast-and colon carcinoma. Besides potent activity as a monotherapy agent, the anti-MARCO antibody enhanced the effect of immune-checkpoint therapy targeting CTLA-4. 7 An important future research target will be to further define the function of the MARCO expressing macrophages in human cancer. This includes the relative contribution to antiinflammatory processes and tumor supportive functions. Macrophages are plastic cells and respond to specific cues in the environment and it has been shown that in vitro polarized macrophages may not be informative of the situation in vivo. 45 We here observed fewer macrophages expressing MARCO in comparison to the other lineage markers analyzed in this study, indicating that MARCO expression defines a specific subset of TAMs. Although the number of MARCO positive macrophages generally correlated to the total number of CD68-positive macrophages, the relative fraction of the MARCO-positive macrophage subset varied between individual cases. MARCO-positive cells present in the stromal compartment showed a noteworthy pattern of localization in some cases, where the macrophages tended to surround the tumor islets. Thus, TAMs expressing MARCO could contribute to an immunosuppressive barrier protecting the tumor cell nests. This would make them an interesting target in combination with other immune regulators where access to the tumor and local inflammatory environment is beneficial. Indeed, co-expression of MARCO and PD-L1 was seen in macrophages in and around the tumor cell nests, and MARCO transcript levels correlated to the expression of the checkpoint molecules PD-L1, PD-1, CTLA-4 and VISTA.
We performed a comprehensive transcriptomic analysis focused on macrophage biology and T-cell regulation. The network enrichment analysis revealed numerous highly enriched gene sets, partly overlapping and associated with both immune stimulatory and immune suppressive functions, which indicated a broad activation of macrophages, T-cells, B-cells, neutrophils and NK-cells. In concert, the analysis provided links to activating (IFNg, IL1, IL6 and IL12) and suppressive/regulatory (TGFb, IL10, IL17 and IL4) cytokine/ chemokine signaling pathways. These results might be explained by patterns in the clustering analysis, where a large patient population exhibited high overall expression in the clusters representing regulatory, exhausted and cytotoxic T-cells-and macrophage genes. This finding indicates a population of tumors in our cohort belonging to the "immune-inflamed" subgroup of cancers as reviewed by Chen and Mellman. 46 Indeed, a second group of patients displayed overall low expression in the represented immune gene clusters reminiscent of the described "immune desert" subgroup. Notably, a third group of tumors revealed a more regulated pattern with a high expression of macrophage genes, including MARCO, together with elevated expression in the gene clusters linked to regulatory and exhausted T cells. This subgroup of patients fits the published phenotype of MARCO-positive immunosuppressive macrophages, and the described immunohistochemistry and immunofluorescence data. However, the transcriptomics data should be interpreted with caution. Notably, gene expression levels from a paired fresh-frozen sample of whole tissue that apart from cancer tissue contains potentially inflamed or infected nontumorous tissue, could be principally different from estimated protein levels of the same genes in sections from a TMA-core representing a different tumor area. Also, compartment specific expression patterns cannot be appreciated in RNA-seq data from a crude tissue extract.
In conclusion, we have characterized lung cancer TAMs and established MARCO as a potential predictive marker for a tumor promoting macrophage subset that could be targeted with established anti-MARCO antibodies. Our results highlight the prospect that anti-MARCO treatment could improve the response of available immune-modulatory drugs. It is likely that macrophage profiling will form one important axis in future multimodal predictive testing for personalized immunotherapy. 47 
